Experienced in Visceromegaly

Dr. Sunil Gandhi

Radiology
Bay Imaging Consultants Medical Group Inc.
2125 Oak Grove Rd Ste 200, 
Walnut Creek, CA 
Experienced in Visceromegaly
Bay Imaging Consultants Medical Group Inc.
2125 Oak Grove Rd Ste 200, 
Walnut Creek, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sunil Gandhi is a Radiologist in Walnut Creek, California. Dr. Gandhi is rated as an Experienced provider by MediFind in the treatment of Visceromegaly. His top areas of expertise are Osteopenia, Melorheostosis with Osteopoikilosis, Melorheostosis, and Chronic Cough.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in CA
Hospital Affiliations
John Muir Medical Center - Walnut Creek Campus
John Muir Medical Center - Concord Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Bay Imaging Consultants Medical Group Inc.
2125 Oak Grove Rd Ste 200, Walnut Creek, CA 94598
Other Locations
Bay Imaging Consultants Medical Group Inc.
140 Brookwood Rd Ste 100, Orinda, CA 94563

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

6 Total Publications

MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Journal: Radiology
Published: September 03, 2024
Similar Doctors
Distinguished in Visceromegaly
Dr. William Harvey
Radiology
Distinguished in Visceromegaly
Dr. William Harvey
Radiology

California Pacific Medical Center

3700 California St, 
San Francisco, CA 
 (24.3 miles away)
650-750-3025
Languages Spoken:
English
See accepted insurances

William Harvey is a Radiologist in San Francisco, California. Dr. Harvey is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. His top areas of expertise are Visceromegaly, Chronic Inflammatory Response Syndrome (CIRS), Progressive Familial Intrahepatic Cholestasis Type 1, and Progressive Familial Intrahepatic Cholestasis Type 3.

Distinguished in Visceromegaly
Dr. Edward Baker
Radiology
Distinguished in Visceromegaly
Dr. Edward Baker
Radiology

California Pacific Medical Center-Van Ness Campus

1101 Van Ness Ave, 
San Francisco, CA 
 (22.6 miles away)
415-600-3232
Languages Spoken:
English
See accepted insurances

Edward Baker is a Radiologist in San Francisco, California. Dr. Baker is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. His top areas of expertise are Gallbladder Disease, Visceromegaly, Progressive Familial Intrahepatic Cholestasis Type 2, Progressive Familial Intrahepatic Cholestasis Type 3, and Endoscopy.

Distinguished in Visceromegaly
Dr. Peter Poullos
Radiology
Distinguished in Visceromegaly
Dr. Peter Poullos
Radiology

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (34.0 miles away)
650-723-6855
Languages Spoken:
English
See accepted insurances

Peter Poullos is a Radiologist in Stanford, California. Dr. Poullos is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. His top areas of expertise are Visceromegaly, Fibrolamellar Carcinoma, Lymphofollicular Hyperplasia, and Progressive Familial Intrahepatic Cholestasis Type 1.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gandhi's expertise for a condition
ConditionClose
      View All 43 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile